Accrued expenses and other current liabilities (Tables)

9 Months Ended

Sep. 30, 2024

Payables and Accruals [Abstract]

Summary of Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities consist of the following (in thousands):

	As of September 30, 2024		As of December 31, 2023
Collaboration research costs	$	7,053	$	5,681
Employee compensation, including severance for restructuring	6,591		4,639
Royalties	4,022		9,702
Clinical and contract research organization costs	904		990
Deferred transition services income (1)	457		—
Manufacturing costs	—		1,764
Property, plant, and equipment	—		279
Other	4,195		2,633
Total accrued expenses and other current liabilities	$	23,222	$	25,688

(1) Refer to Note 3, Asset Purchase Agreements, for further information regarding deferred transition services income relating to the Novo Transaction.